A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma
A randomized clinical trial of radiation therapy versus thermoradiotherapy in stage IIIB cervical carcinoma
复制标题
DOI：
10.1080/02656730903092018
复制
发表时间：
2009-01-01
影响因子：
3.1
通讯作者：
Sawada, S.
中科院分区：
文献类型：
--
作者：
Harima, Y.;Nagata, K.;Sawada, S.
为了阐明热放射疗法对FIGO IIIB期宫颈癌的作用，对接受放射疗法或热放射疗法治疗的患者的临床反应和生存率进行了研究。 40 例 IIIB 期宫颈癌患者接受骨盆外束照射联合铱 192 高剂量腔内近距离放射治疗。所有患者随机分为以下两组：放疗（RT）组20例，仅接受单纯放疗；热放射治疗（TRT）组有 20 名患者，除了放疗外还接受了 3 次热疗。本研究的主要终点是局部完全缓解和生存。 RT 组的完全缓解率为 50%（20 人中的 10 人），而 TRT 组的完全缓解率为 80%（20 人中的 16 人）（p = 0.048）。接受TRT治疗的患者的3年总生存率和无病生存率（58.2%和63.6%）优于接受RT治疗的患者（48.1%和45%），但这些差异并不显着。接受TRT治疗的患者的3年局部无复发生存率（79.7%）显着优于接受RT治疗的患者（48.5%）（p = 0.048）。本试验中提供的 TRT 具有良好的耐受性，并且与单独放疗相比，不会显着增加相关的临床急性或长期毒性。对于FIGO IIIB 期宫颈癌患者，TRT 比 RT 具有更好的治疗反应和 3 年局部无复发生存率。
To clarify the role of thermoradiotherapy for FIGO Stage IIIB cervical carcinomas, both the clinical response and survival of patients treated with radio-or thermoradiotherapy were investigated. Forty patients with Stage IIIB uterine cervix carcinoma were treated with external beam irradiation to the pelvis, combined with iridium 192 high-dose-rate intracavitary brachytherapy. All patients were divided randomly into the following two groups: the radiotherapy (RT) group of 20 patients, who underwent radiotherapy alone; and the thermoradiotherapy (TRT) group of 20 patients, who underwent three sessions of hyper-thermia in addition to radiotherapy. The primary endpoint of this study was local complete response and survival. A complete response was achieved in 50% (10 of 20) in the RT group versus 80% (16 of 20) in the TRT group (p = 0.048). The 3-year overall survival and disease-free survival of the patients who were treated with TRT (58.2 and 63.6%) were better than those of the patients treated with RT (48.1 and 45%), but these differences were not significant. The 3-year local relapse-free survival of the patients who were treated with TRT (79.7%) was significantly better than that of the patients treated with RT (48.5%) (p = 0.048). TRT, as delivered in this trial, was well tolerated and did not significantly add to either the relevant clinical acute or long-term toxicity over radiation alone. TRT resulted in a better treatment response and 3-year local relapse-free survival rate than RT for patients with FIGO Stage IIIB cervical carcinoma.